Australia Clears Novartis Buy Of Alcon Without Key Eye-care Line
This article was originally published in PharmAsia News
Australian authorities have given their permission for the merger of Switzerland's Novartis AG and Alcon Laboratories, based in the United States, but incorporated in Switzerland
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.